🔶Evolution
Non-Alcoholic Fatty Liver Disease (NAFLD) or named as Metabolic associated fatty liver disease (MAFLD), is the most common chronic liver disease globally, with a prevalence rate of 25%. With the advance in the disease control of HBV and HCV by mass HBV vaccination and antivirals, MAFLD has become the major cause of end-stage liver disease, hepatocellular carcinoma (HCC), and liver transplantation in Europe and USA, which will lead to global health threat with significant economic impact. However, there remain many huge unmet needs in the control of MAFLD, including the pathogenetic mechanisms, prevention, treatment and therapeutic targets.

🔶Purpose of Establishment

To resolve the threats of MAFLD, we establish “The Center of Excellence for Metabolic Associated Fatty Liver Disease(CEMAFLD)” to conduct a comprehensive investigation on MAFLD, including epidemiology, pathogenesis, diagnosis, management, as well as the development of therapeutic agents and medical devices. 
We expect to accomplish international and nationwide epidemiological investigation, establish platforms for clinical cohorts, pathological reading, animal models and education, complete pre-clinical trials of potential pharmaceutical targets, publish MAFLD position statement and consensus guidelines, and conduct professional training programs and public health education. We expect the achievement could be served as reference of policy-making for public health. CEMAFLD also responds to cultivating outstanding scientific research talents, providing opportunities for international exchange visits and academic cooperation, and conducting industry-university cooperative development with industries. The CEMAFLD will become the first and leading global MAFLD Center in Asia-Pacific, and continuously reach Sustainable Development Goals.

🔶Key Core Issues

1.Research on the Risk, Pathogenesis, and Prognosis of MAFLD/MASLD in Liver Disease Severity, Disease Progression, and Cancer.
2.Study on the role and mutual influence of viral infections in MAFLD/MASLD (HCV, HBV, Dengue Virus).
3.Exploration of the Risk and Mechanisms of MAFLD/MASLD in Cardiovascular Diseases and Other Extrahepatic Manifestations.
4.The Impact of External Factors on MAFLD/MASLD.
5.Study on the Effects and Mechanisms of Novel Drugs in NASH Mice.
6.Study on the Effects and Mechanisms of Potential Targets and Biomarkers in MAFLD/MASLD.